Navigation Links
Ceelox Offers Beta Release of Ceelox ID 7 for Personal Computers
Date:5/2/2011

TAMPA, Fla., April 6, 2011 /PRNewswire/ -- Ceelox, Inc. (OTCBB: CELO) announced today the beta release of Ceelox ID 7 PC Edition which operates on computers running the Windows 7 Operating System.    

Ceelox has redesigned their authentication approach to leverage the recent capability of Windows 7.  In Windows 7, the Windows Biometric Framework (WBF) provides support for fingerprint biometric devices through a new set of components. These components improve the quality, reliability, and consistency of the user experience for customers who have fingerprint biometric devices.

Ceelox ID PC Edition which controls local access to a user's computer and provides secure login sessions for programs such as Microsoft Outlook and other applications requiring traditional user name and password.  The authentication of a user's biometric live swipe matched locally on the computer grants access only to the registered users.  This offers increased security and restricts access to a user's applications and data on their personal computer.

"By incorporating the functionality of the Windows Biometric Framework into our design, Ceelox enables the plug-in-play mentality of interoperating with any fingerprint sensor that is compatible with the WBF.  We can now offer Ceelox ID PC Edition across multiple Microsoft platforms e.g. Windows XP, Windows Vista, and Windows 7.  This is a significant step forward for the company," states Gerry Euston, CEO, Ceelox.  

About Ceelox, Inc.

Ceelox, Inc. is a developer of biometric security and encryption software solutions for financial institutions, healthcare companies, utilities, government agencies and other organizations for whom information access are key concerns.  Its security and encryption tools are easy to deploy, simple to use, cost-effective and affordable for organizations of all sizes.  

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in our Form 8-K filed with the Securities and Exchange Commission on February 12, 2010 and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

For more information visit our website at www.ceelox.com


'/>"/>
SOURCE Ceelox, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Ceelox Offers Beta Release of Ceelox ID 7 for Personal Computers
2. Ceelox Provides Biometric Identity Access to Cloud Applications
3. Worm genome offers clues to evolution of parasitism
4. Advance offers revolution in food safety testing
5. Light pollution offers new global measure of coral reef health
6. Rong Li Lab offers insight into adaptive ability of cells
7. International public-private partnership offers new paradigm for medicinal chemistry
8. UC Davis discovery offers hope for treating kidney cancer
9. New paper offers key insights into how new species emerge
10. Study offers clues to beating hearing loss
11. Fighting global warming offers growth and development opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
Breaking Biology Technology: